HippoFi and its subsidiary PUR Biologics have FDA 510(k) clearance for ActiveOrb technology and a global license from Zimmer Biomet to use in the spine market, according to a Sept. 7 news release. The companies are working under a joint commercialization research agreement to produce spine-specific products.
The synthetic biomaterial is expected to launch in 2024.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
